Quantum Group completes dosing in 180-day study of Lucid-MS

Quantum BioPharma announces that oral dosing of Lucid-21-302, Lucid-MS, is complete in both the 180-day toxicity and toxicokinetic studies. These studies will support the Investigational New Drug, IND, application with the US FDA, including the design of a Phase 2 trial of Lucid-MS in people with multiple sclerosis, MS. Anthony Durkacz, Founder and executive co-chairman of Quantum BioPharma added, “By completing these 180-day toxicity studies, we are now two important steps closer to initiating the Phase 2 trial of Lucid-MS in people with multiple sclerosis. We are very excited about the potential of this new, first-in-class treatment to prevent disease progression and inhibit demyelination in MS.”